Cargando…
Engineering the common cold to be a live-attenuated SARS-CoV-2 vaccine
According to the American Centers for Disease Control and Prevention, people in all age groups catch two or more “colds” per year, at least half of which are caused by human rhinoviruses. Despite decades of effort, there are no vaccines or drugs against rhinovirus infections and even social distanci...
Autor principal: | Kasman, Laura M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516391/ https://www.ncbi.nlm.nih.gov/pubmed/36189239 http://dx.doi.org/10.3389/fimmu.2022.871463 |
Ejemplares similares
-
SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses
por: Schmidt, Katja G., et al.
Publicado: (2021) -
Intranasal administration of cold-adapted live-attenuated SARS-CoV-2 candidate vaccine confers protection against SARS-CoV-2
por: Abdoli, Mohsen, et al.
Publicado: (2022) -
Immunoinformatics Identification of the Conserved and Cross-Reactive T-Cell Epitopes of SARS-CoV-2 with Human Common Cold Coronaviruses, SARS-CoV, MERS-CoV and Live Attenuated Vaccines Presented by HLA Alleles of Indonesian Population
por: Gustiananda, Marsia, et al.
Publicado: (2022) -
Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV
por: Bessen, Clara, et al.
Publicado: (2022) -
Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines
por: Reche, Pedro A.
Publicado: (2020)